IntoCell signs MTA with ADC Therapeutics
IntoCell recently announced the signing of a Material Transfer Agreement (MTA) with option to license with ADC Therapeutics SA Under the agreement, IntoCell, a South Korean biotech developing novel antibody drug conjugate (ADC) platform technologies, will provide proprietary drug-linkers developed using their proprietary Ortho-Hydroxy Protected Aryl Sulfate (OHPASTM) system and payload modification technology (PMT). ADC […]
